BB Biotech AG
Other OTCTotal Valuation
BB Biotech AG carries a market capitalization of 4.22B, placing it among publicly traded companies globally. Its enterprise value stands at 2.25B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.22B |
| Enterprise Value | 2.25B |
Share Statistics
BB Biotech AG currently has 55.15M shares outstanding.
| Shares Outstanding | 55.15M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
BB Biotech AG trades at a trailing price-to-earnings ratio of 7.44. The price-to-sales ratio is 7.15, and the price-to-book ratio stands at 0.99.
| PE Ratio | 7.44 |
| PS Ratio | 7.15 |
| PB Ratio | 0.99 |
| P/TBV Ratio | 0.99 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 6.18 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Efficiency
| Return on Equity (ROE) | 15.13 |
| Return on Assets (ROA) | 15.25 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, BB Biotech AG has paid 56,000.00 in income taxes, reflecting an effective tax rate of 0.02.
| Income Tax | 56,000.00 |
| Effective Tax Rate | 0.02 |
Stock Price Statistics
BB Biotech AG's stock has gained approximately 0.12743492% over the past 52 weeks. The 50-day moving average sits at 43.85, while the 200-day moving average is 43.85.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.12743492% |
| 50-Day Moving Average | 43.85 |
| 200-Day Moving Average | 43.85 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BB Biotech AG generated 364.10M in revenue and converted that into 350.07M in net income, yielding earnings per share of 6.37.
| Revenue | 364.10M |
| Gross Profit | N/A |
| Operating Income | N/A |
| Pretax Income | 350.12M |
| Net Income | 350.07M |
| EBITDA | N/A |
| EBIT | N/A |
| Earnings Per Share (EPS) | 6.37 |
Balance Sheet
| Cash & Cash Equivalents | 354.97M |
| Total Debt | N/A |
| Net Debt | -354.97M |
| Equity (Book Value) | 2.64B |
| Book Value Per Share | 48.09 |
| Working Capital | N/A |
Margins
BB Biotech AG operates with a gross margin of 100.00, reflecting its pricing power and cost economics.
| Gross Margin | 100.00 |
| Operating Margin | N/A |
| Pretax Margin | 96.16 |
| Profit Margin | 96.15 |
| EBITDA Margin | N/A |
Dividends & Yields
The company's payout ratio of 35.45 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 2.26 |
| Dividend Yield | N/A |
| Payout Ratio | 35.45 |
| Shareholder Yield | 4.85 |
| FCF Yield | N/A |
Scores
BB Biotech AG posts an Altman Z-Score of 200.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 200.34 |